Oncostatin M

A cytokine with both pro- and anti-inflammatory actions that depend upon the cellular microenvironment. Oncostatin M is a 28 kDa monomeric glycoprotein that is similar in structure to LEUKEMIA INHIBITORY FACTOR. Its name derives from the the observation that it inhibited the growth of tumor cells and augmented the growth of normal fibroblasts.

Networked: 375 relevant articles (4 outcomes, 40 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Richards, Carl D: 13 articles (09/2014 - 05/2002)
2.	Blanchard, Frédéric: 7 articles (11/2012 - 12/2003)
3.	Tanaka, Minoru: 5 articles (08/2015 - 08/2008)
4.	Jorcyk, Cheryl L: 5 articles (03/2015 - 01/2004)
5.	Heymann, Dominique: 5 articles (11/2012 - 11/2004)
6.	Miyajima, Atsushi: 4 articles (08/2015 - 08/2008)
7.	Ryan, Randall E: 4 articles (03/2015 - 01/2004)
8.	Kaun, Christoph: 4 articles (10/2011 - 03/2008)
9.	Rega, Gersina: 4 articles (10/2011 - 03/2008)
10.	Wojta, Johann: 4 articles (10/2011 - 03/2008)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2015 - "Oncostatin M (OSM), a pleiotropic cytokine, can either promote or inhibit the growth of tumors derived from specific tissues. " 01/01/2015 - "Moreover, increased neutrophil autophagy also correlated with sustained production of pro-metastatic oncostatin M and MMP9 and advanced migration of cancer cells. " 12/01/2014 - "A combination of techniques, including transcriptomics, proteomics, and kinomics enabled us to identify paracrine secretion of oncostatin M (OSM) by cancer-associated adipose tissue. " 03/01/2014 - "Oncostatin M signaling via the JAK/STAT pathway was the most relevant pathway, with immunohistochemical staining showing that OSM and LIF, both included in this pathway, were overexpressed in tumors. " 08/01/2013 - "Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI."
2.	Breast Neoplasms (Breast Cancer) 12/01/2008 - "Recent studies in breast cancer cell lines have shown that oncostatin M (OSM) not only inhibits proliferation but also promotes cell detachment and enhances cell motility. " 07/01/2003 - "Our previous studies have shown that treatment of MCF-7 breast cancer cells with cytokine oncostatin M (OM) results in a growth arrest and a concurrent decrease in p53 expression. " 07/30/2014 - "Concordantly, hypoxic regions of human breast-cancer specimen exhibited elevated Eotaxin and Oncostatin M levels with concurrently elevated M2-macrophage content. " 03/20/2014 - "Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer." 04/01/2012 - "We hypothesised that the inflammatory cytokine oncostatin M (OSM) can downregulate ER expression in breast cancer. "
3.	Lung Neoplasms (Lung Cancer) 12/20/2004 - "[Experimental study on lung cancer-targeted oncostatin M gene therapy induced by ionizing radiation]." 12/20/2004 - "To improve the efficacy and selectivity of gene therapy for lung cancer through inducing oncostatin M (OSM) gene expression by radiation via the early growth response gene-1 (Egr-1) promoter. " 04/01/2004 - "To improve the efficacy of radiogenetic therapy for lung cancer, a hypoxia/radiation dual-sensitive promoter was constructed to enhance the expression of oncostatin M (OSM) in transfected cells exposed to radiation under hypoxia. " 08/01/2006 - "Inhibition effect of Oncostatin M on metastatic human lung cancer cells 95-D in vitro and on murine melanoma cells B16BL6 in vivo." 01/01/1990 - "Six out of 7 lung cancer cell lines were inhibited by oncostatin M, but none of 6 colon cancer cell lines were affected. "
4.	Anoxia (Hypoxia) 07/01/2009 - "Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling." 04/01/2004 - "To improve the efficacy of radiogenetic therapy for lung cancer, a hypoxia/radiation dual-sensitive promoter was constructed to enhance the expression of oncostatin M (OSM) in transfected cells exposed to radiation under hypoxia. " 07/30/2014 - "Here, we show that hypoxia-primed cancer cells chemoattract and polarize macrophages to pro-angiogenic M2-polarized subtype via Eotaxin and Oncostatin M. " 04/01/2004 - "[Oncostatin M gene therapy in mice bearing lung adenocarcinoma xenograft using a hypoxia/radiation dual-sensitive promoter]." 07/01/2009 - "The interleukin-6-type cytokine oncostatin M (OSM) acts via the Janus kinase/signal transducer and activator of transcription pathway as well as via activation of mitogen-activated protein kinases and is known to critically regulate processes such as liver development and regeneration, hematopoiesis, and angiogenesis, which are also determined by hypoxia with the hypoxia-inducible factor 1alpha (HIF1alpha) as a key component. "
5.	Myocardial Infarction 04/01/2004 - "Oncostatin-M may contribute to the process of healing after myocardial infarction." 11/04/2011 - "Here, we demonstrate that oncostatin M (OSM) is a major mediator of cardiomyocyte dedifferentiation and remodeling during acute myocardial infarction (MI) and in chronic dilated cardiomyopathy (DCM). " 05/01/2014 - "The recent finding that the cytokine oncostatin M (OSM) is pivotal for cardiomyocyte dedifferentiation and exerts strong protective effects during myocardial infarction highlights the role of cytokines as potent stimulators of cardiac remodeling. "

Related Drugs and Biologics

1.	Cytokines
2.	bevacizumab
3.	Interleukin-6 (Interleukin 6)
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Leukemia Inhibitory Factor
6.	Carbon Monoxide
7.	Interleukin-1alpha (Interleukin 1 alpha)
8.	Interleukin-11 (Interleukin 11)
9.	Ciliary Neurotrophic Factor (CNTF)
10.	Interleukins

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Root Planing
3.	Transplantation (Transplant Recipients)
4.	Angioplasty (Angioplasty, Transluminal)
5.	Therapeutics